About Us
At NoRD Bio, we harness the transformative potential of disease monitoring to redefine cancer care for patients and clinicians.
Our Mission
Enhancing Access
Developing innovative, cost-effective tools to make MRD testing widely available.
Simplifying Usability
Creating intuitive technologies with rapid turnaround times and actionable results for clinicians and patients.
Driving Better Outcomes
Enabling earlier relapse detection, personalized treatments, and improved survival rates through precise MRD monitoring.
Leadership
Ignaty Leshchiner, PhD
Co-Founder
Associate Professor in Computational Biomedicine at Boston University School of Medicine. Expert in cancer computational biology, genomic technologies, and AI methods for unraveling tumor development, treatment evasion, and metastasis progression.
Dimitri Livitz, PhD
Co-Founder, Head of Data Science
Head of Data Science and Genomics. Formerly at the Broad Institute of Harvard and MIT, co-author of high-profile publications in Nature, Nature Medicine, and Cell. PhD from Columbia University in Bayesian experimental design.
Paul Trukhanov
Co-Founder
Software Architect in Machine Learning at Dana-Farber Cancer Institute. Experienced startup entrepreneur with expertise in biotechnology, healthcare, and data-intensive software engineering, with two successful startup exits.
Elizaveta Leshchiner, PhD
Co-Founder
Focused on experimental and computational cancer biology with strong expertise in technology and high-throughput assay development. PhD from Harvard University; leads a team of scientists at the Broad Institute of Harvard and MIT.
Andrew Jacobs, JD
Co-Founder, CEO
As CEO Andy has a 40-year record of successfully starting, managing and growing multitude of small and medium sized companies, several of which were subsequently sold to public companies. He has served as CEO and a Board Member for companies in the area of computational services and data management for cancer patients, as well as in other fields, and has been heavily involved in several non-profit enterprises, including a foundation providing patient access to experimental cancer vaccines under FDA regulations.
Senior Advisors
Ida Pavlichenko, PhD
Senior Advisor
Serial entrepreneur and R&D leader, MIT TR Innovators Under 35. Focused on translating advanced science into practical medical solutions.
Roger Jacobs, MBA
Senior Advisor
40 years in management and business development in SaaS, bioinformatics, and biological services.
Partnering with Us
We specialize in Next-Generation Sequencing (NGS) assays for cancer research. Our precision-driven approach delivers groundbreaking insights into tumor biology, therapeutic efficacy, and patient outcomes.
What Sets Us Apart?
Unmatched Expertise: Years of experience customized to meet unique challenges.
Innovative Approaches: Cutting-edge methodologies that drive progress.
Client-Centric Support: Committed to equipping clients with the tools and expertise they need.